Latest "Galectin Therapeutics" News Stories

21:23 EST 20th November 2014 | BioPortfolio

Here are the most relevant search results for "Galectin Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Galectin Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Galectin Therapeutics for you to read. Along with our medical data and news we also list Galectin Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Galectin Therapeutics Companies for you to search.

Showing "Galectin Therapeutics" News Articles 1–25 of 106

Relevant

Harwood Feffer LLP Announces Investigation of Galectin Therapeutics Inc.

NEW YORK, July 31, 2014 /PRNewswire/ --Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against Galectin Therapeutics Inc. ("Galectin" or the "Company") (NASDAQ: GALT) and its ...

Galectin Therapeutics Announces First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of GR-MD-02

NORCROSS, Ga., July 22, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the first patient has been dosed in...

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Galectin Therapeutics, Inc. (GALT) to Contact the Firm

NEW YORK, NY--(Marketwired - August 23, 2014) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Galectin Therapeutics, Inc. ("Galectin" or the "Company") (NASDAQ...

Galectin Therapeutics Announces That Oral Treatment With Galectin-3 Inhibitor GR-MD-02 is Efficacious in Preclinical Model of Fatty Liver Disease With Fibrosis

NORCROSS, Ga., June 23, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that a preclinical study in a mouse model of NASH (non-alcoholic steatohepatitis, or fatty liver disease) demonstrated that oral administration of the Company's lead galectin-3 inhibitor, GR-MD-02, r...

Endocytosis: Bend it like galectin 3

Galectin 3 binds to glycosylated cargos and glycosphingolipids, which leads to membrane bending and clathrin-independent carrier biogenesis.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics, Inc. - GALT

NEW YORK, July 29, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galectin Therapeutics, Inc. ("Galectin" or the "Company") (NASDAQ: GALT). Such investors are...

Galectin Therapeutics: Why This Penny Stock Dressed Up By Stock Promoters Is A Short

ByChristopher Drose: Galectin Therapeutics (NASDAQ:GALT) "It's now or never, come hold me tight/ Kiss me my darling / be mine tonight / Tomorrow will be too late/ it's now or never"- Elvis Presley "It's Now or Never" GALT CEO Dr. Peter Traber at his recent Elvis Presley-themed Las Vegas wedding.Galectin Therapeutics is a development stage biotechnology company that is developing drugs for fib...

Galectin-3 and Plasma Cytokines in Patients With Acute MI

Could the protein galectin-3 be useful as a circulating biomarker of inflammation associated with acute myocardial infarction? Laboratory Medicine

GALECTIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Galectin Therapeutics Inc. -- GALT

NEW ORLEANS, July 31, 2014 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 29, 2014 to file lead plaintiff applications in a securities class action lawsuit against Galectin Therapeutics Inc. (Nasdaq:GALT), if they purchased the Company's securities during the pe...

GALECTIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Galectin Therapeutics Inc. - GALT

NEW ORLEANS, Aug. 15, 2014 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 29, 2014 to file lead plaintiff applications in a securities class action lawsuit against Galectin Therapeutics Inc. (Nasdaq:GALT), if they purchased the Company's securities during the pe...

Galectin Therapeutics Gets Punished For Phase 1 Trial, But Wall Street Is Missing The Point

Shares of Galectin Therapeutics (GALT) were punished on Tuesday July 29th after reporting the phase 1 results of its NASH trial with patients in the 2nd cohort. The stock tanked as much as 60%  on the news, but the sell… Continue Reading →

Investor Alert: Holzer & Holzer Announces Class Action Filed on Behalf of Investors in Galectin Therapeutics Inc.; Investors with Losses Exceeding $50,000 Encouraged to Contact the Firm

Holzer & Holzer, LLC announces that a class action lawsuit has been filed in the United States District Court for the District of Nevada on behalf of investors who purchased Galectin Therapeutics, Inc. (“Galectin” or the “Company”) (NASDAQ: GALT) securities between January 6, 2014 and July 28, 2014. The complaint alleges that during the relevan...

Bristol-Myers signs exclusive option deal to buy Galecto and new Galectin-3 inhibitor

Bristol-Myers Squibb (BMS) has signed an exclusive option agreement to acquire Denmark-based Galecto Biotech and secure worldwide rights to a new inhaled inhibitor of galectin-3, TD139.

Ryan & Maniskas, LLP Announces Investigation of Galectin Therapeutics, Inc.

WAYNE, Pa., July 30, 2014 /PRNewswire/ -- Ryan & Maniskas, LLP has commenced an investigation into potential securities law violations by certain officers of Galectin Therapeutics, Inc. ("Galectin" or the "Company") (NASDAQ: GALT). Galectin shareholders who purchased Galectin shares should contact Richard A. Maniskas, Esquire at 877-316-3218 or at rmaniskas@rmclasslaw.com to learn more ...

Bristol-Myers Squibb to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor

Bristol-Myers Squibb Company and Galecto Biotech AB have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of g...

Attention Galectin Therapeutics Inc. Investors: Galectin Misled Investors According to a Recently Filed Class Action

SAN DIEGO and NORCROSS, Ga., Aug. 1, 2014 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Galectin Therapeutics Inc. (NASDAQ: GALT) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of Nevada. The complaint alleges that the company and certain of its officers and directors violated the Securitie...

Galectins CLIC cargo inside

Clathrin-independent endocytosis removes membrane receptors and other proteins from the cell surface, yet the mechanisms controlling this process remain unclear. Galectin-3 is now shown to regulate the biogenesis of a subpopulation of clathrin-indepe...

Galectin-3 drives glycosphingolipid-dependent biogenesis of clathrin-independent carriers

Many cell surface receptors are internalized by clathrin-independent endocytosis, but how clathrin-independent carriers (CLICs) are generated at the plasma membrane remained unclear. Johannes and colleagues now report that galectin-3 (Gal3) binds to ...

Patent Awarded for Innovative Galectin-3 Plasmapheresis Therapy

SANTA ROSA, Calif., Sept. 4, 2014 /PRNewswire/ -- Isaac Eliaz, MD, MS, LAc has been awarded a USA patent as well as additional international patents for a therapeutic process that allows for the removal of excess galectin-3 from the circulatory system using plasmapheresis. The Galectin-3 Plasmapheresis Therapy patent is the first-ever granted for this type of therapy. Dr. Eliaz is a pioneer...

Bristol-Myers Squibb to acquire Galecto Biotech AB and its novel Galectin-3 Inhibitor in development for Idiopathic Pulmonary Fibrosis

Bristol-Myers Squibb Company and Galecto Biotech AB have announced that the companies, together with the Galecto shareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and ga...

Galectin falls on NASH data for GR-MD-02

Galectin Therapeutics Inc. (NASDAQ:GALT) fell $8.84 (61%) to $5.50 on Tuesday after reporting data from the Phase I GT-020 trial of the company's GR-MD-02 to treat non-alcoholic steatohepatitis (NASH) with advanced hepatic fibrosis. In nine patients ...

GALECTIN 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Securities Class Action Lawsuit Against Galectin Therapeutics Inc. - GALT

NEW ORLEANS, LA -- (Marketwired) -- 09/26/14 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financia...

Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Galectin Therapeutics, Inc.

NEW YORK, July 30, 2014 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Galectin Therapeutics, Inc. ("Galectin Therapeutics" or the "Company") (NasdaqCM: GALT).  Such investors are advised to contact Edward N. Gewirtz or his investor relation's coordinator Eitan Kimelman at info@bgand...

Galectin Therapeutics, Inc. (GALT) - Financial and Strategic SWOT Analysis Review

Recently added to the BioPortfolio report store, Galectin Therapeutics, Inc. (GALT) - Financial and Strategic SWOT Analysis Review is a new report from GlobalData published on 2014-08-10. This 25-page report is available in PDF from $300. Summary This comprehensive SWOT profile of Galectin Therapeutics, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations...

Galectin Therapeutics Added to Russell 2000 Index

NORCROSS, Ga., July 9, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced that it has been added to the Russell 3000® Index and Russell 2000® Index when Russell Investments reconstituted its comprehensive set of U.S. and global equity indexes on June 27, 2014. "We are pl...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks